🚫 Avoid
Listed
Hospital
Paras Healthcare Limited IPO
₹1450 Cr · Fresh Issue & OFS · Hospital
Price Band
₹660 – ₹693
Lot: 21 shares (₹14,553)
GMP (Grey Market)
₹13 (+1.88%)
Est. listing ₹706
Issue Size
₹1450 Cr
Fresh Issue & OFS
Market Cap
₹7498.34 Cr
At upper band
P/E Ratio
171.1x
P/S: 4.7x
Listing Date
28 Oct 2026
BSE & NSE
IPO Timeline
✓
Opens
21 Oct 2026
✓
Closes
23 Oct 2026
✓
Allotment
26 Oct 2026
✓
Refund
27 Oct 2026
📈
Listing
28 Oct 2026
IPO India Hub: Strong Avoid
Conviction
2/10
The company is valued at 4.28× the healthcare sector midpoint (171.1x P/E vs 40x benchmark) with no margin justification to support this premium. Critical red flags include a 39.6% revenue CAGR decline over two years, a 3.53× debt-to-equity ratio, complete promoter exit post-issue, and 65.5% OFS—all pointing to distressed capital structure and founder loss of confidence.
Listing Performance
Issue Price
₹693
Allotment price
Listing Price
₹720
+3.9% on listing day
Current Price (CMP)
₹737.15
+6.4% vs issue
Listed On
28 Oct 2026
BSE & NSE
Our Analysis — Key Points
✓ Strength
Strong EBITDA margin and PAT recovery
The company reported a 20.6% EBITDA margin and 306.9% PAT CAGR over two years, suggesting operational leverage in the core hospital business. Net profit grew from ₹3.0 Cr (FY-2) to ₹49.7 Cr (FY0), indicating improved profitability trajectory in recent periods.
✓ Strength
Positive grey market sentiment
The ₹92 GMP (13.28% premium to upper band) signals cautious investor interest and exceeds the 15% Mainboard threshold for bullish signals. This suggests some market confidence in the healthcare sector and the company's operational recovery.
⚠ Risk
Severe revenue contraction and data anomaly
Revenue collapsed 39.6% over two years (FY-2: ₹1314.2 Cr → FY0: ₹478.8 Cr), a catastrophic decline for a hospital operator. The FY0 figure of ₹478.8 Cr appears to be a partial-year or one-time disruption; if annualized, this suggests operational crisis or accounting restatement risk.
⚠ Risk
Unsustainable leverage and debt-driven capital raise
The 3.53× debt-to-equity ratio is dangerously high for a healthcare operator (non-infrastructure baseline <1.5×). Critically, ₹320.9 Cr of the ₹1450 Cr IPO proceeds (22% of gross raise) is earmarked for debt repayment, confirming the IPO is primarily a refinancing exercise, not growth capital.
⚠ Risk
Complete promoter exit and maximum OFS
Promoter holding drops from 72.8% pre-issue to 0% post-issue, signaling total founder exit. OFS comprises 65.5% of the issue size—well above the 30% preference threshold—indicating insiders are liquidating holdings rather than investing alongside public shareholders.
₹ Valuation
Extreme valuation multiple with no margin buffer
At 171.1x P/E (4.28× the 40x healthcare sector midpoint), the company trades at a 328% premium to sector norms. With NPM of only 10.4% (below the 15% threshold for premium valuation), there is no earnings quality or margin story to justify this multiple. The P/S ratio of 4.7x is also elevated relative to peers.
👁 Watch
Post-listing debt trajectory and hospital utilization
Monitor quarterly debt levels post-IPO and whether the company achieves the stated debt reduction targets. Track hospital bed occupancy, average revenue per bed, and whether the FY0 revenue anomaly was temporary or structural—this will determine if the PAT recovery is sustainable.
Top Analyst Reviews
| Analyst / Firm | Rating | Known For | Review |
|---|---|---|---|
| IPO India Hub Our independent review |
Original analysis based on DRHP & public financials | This page | |
| Dilip Davda Chittorgarh.com |
India's most followed independent IPO analyst | Search on Chittorgarh → | |
| Capital Market (CM Rating) CapitalMarket.com |
Widely-cited "New Issue Monitor" reports | Search on CapitalMarket → | |
| ICICI Securities ICICIdirect Research |
SEBI-registered broker research desk | Visit ICICIdirect → | |
| IPO Guru Analyst Leaderboard ipoguru.in |
Ranks 49 analysts by real IPO outcome accuracy | View leaderboard → |
External links go to each platform's IPO section — search for "Paras Healthcare Limited" to find the specific review. IPO India Hub does not represent the accuracy of third-party ratings.
Company Snapshot
Revenue
₹1605.95 Cr
Net Profit
₹43.83 Cr
Industry
Hospital
Issue Type
Fresh Issue & OFS
Promoters
DR. DHARMINDER KUMAR NAGAR
Lead Managers
JM Financial, BofA Securities and Nuvama Wealth Management
Quick Actions
Frequently Asked Questions
Avoid. The company is valued at 4.28× the healthcare sector midpoint (171.1x P/E vs 40x benchmark) with no margin justification to support this premium. Critical red flags include a 39.6% revenue CAGR decline over two years, a 3.53× debt-to-equity ratio, complete promoter exit post-issue, and 65.5% OFS—all pointing to distressed capital structure and founder loss of confidence.
The current grey market premium (GMP) is ₹13, which is 1.88% above the upper band price of ₹693. This implies an estimated listing price of around ₹706. GMP is informal and unregulated — treat it as a sentiment indicator, not a guarantee.
The minimum lot size is 21 shares. At the upper band price of ₹693, the minimum investment per retail application is ₹14,553. You can apply for up to 13 lots (₹189,189) under the retail category (up to ₹2 lakh).
The IPO opens on 21 Oct 2026. It closes on 23 Oct 2026. Allotment is expected on 26 Oct 2026. Refunds initiate on 27 Oct 2026. Listing on BSE and NSE is on 28 Oct 2026.
The lead managers for the IPO are JM Financial, BofA Securities and Nuvama Wealth Management. Check the SEBI filing for the registrar details.
The IPO listed on 28 Oct 2026 at ₹720 against an issue price of ₹693 (+3.9% on listing day). The current market price (CMP) is approximately ₹737.15 (+6.4% vs issue).
Our analysis recommends <strong>Avoid</strong>. We suggest skipping this IPO before the issue closes on 23 Oct 2026. The minimum investment is ₹14,553 for one lot (21 shares). The company is valued at 4.28× the healthcare sector midpoint (171.1x P/E vs 40x benchmark) with no margin justification to support this premium. Critical red flags include a 39.6% revenue CAGR decline over two years, a 3.53× debt-to-equity ratio, complete promoter exit post-issue, and 65.5% OFS—all pointing to distressed capital structure and founder loss of confidence.
Our analysis recommends <strong>Avoid</strong>. We suggest skipping this IPO before the issue closes on 23 Oct 2026. The IPO is priced at a P/E of 171.1x. Market cap at issue price is ₹7498.34 Cr. As with all IPOs, please read the DRHP and assess your own risk tolerance before investing.
You can apply via UPI through your broker's trading app (Zerodha, Upstox, Fyers, etc.) or via ASBA through your net banking portal. The minimum lot is 21 shares at ₹693 each, costing ₹14,553 per application. The issue closes on 23 Oct 2026, so apply before that date. Step 1: Log in to your broker or bank app. Step 2: Go to IPO section and search for 'Paras Healthcare Limited'. Step 3: Enter the number of lots and UPI ID. Step 4: Accept the mandate on your UPI app.
Explore More